Malajsie - angličtina - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

sandoz products malaysia sdn. bhd. - fludarabine phosphate -

Irsko - angličtina - HPRA (Health Products Regulatory Authority)

bayer limited - fludarabine phosphate - pdr for soln inj/inf - 50 milligram

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - fludarabine phosphate, quantity: 50 mg - injection, intravenous infusion - excipient ingredients: sodium hydroxide; mannitol - fludarabine phosphate for injection usp is indicated for second line therapy in patients with chronic lymphocytic leukemia (cll) and low-grade non-hodgkin's lymphoma (lg-nhl) who have failed other conventional therapies.

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - fludarabine phosphate -

Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - fludarabine phosphate 50mg - powder for injection - 50 mg - active: fludarabine phosphate 50mg excipient: mannitol sodium hydroxide - treatment of b-cell chronic lymphocytic leukaemia.

Izrael - angličtina - Ministry of Health

salomon,levin & elstein ltd - fludarabine phosphate 50 mg / 2 ml - concentrate for solution for injection / infusion - fludarabine - palliative treatment of patients with cll refractory to other therapy. treatment of less malignant non-hodgkin lymphoma of stage 3 to 4 in patients who have not responded to standard therapy with at least one alkylating agent or in whom the disease progressed during or after standard therapy. fludarabine teva is indicated for the initial treatment of patients with b- cell chronic lymphocytic leukaemia (cll) or after first line therapy, in patients with sufficient bone marrow reserves.

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - fludarabine phosphate -

Irsko - angličtina - HPRA (Health Products Regulatory Authority)

actavis group ptc ehf - fludarabine phosphate - lyophilisate for solution for injection - 50 milligram

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - fludarabine phosphate, quantity: 10 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; lactose monohydrate; colloidal anhydrous silica; croscarmellose sodium; magnesium stearate; hypromellose; purified talc; titanium dioxide; iron oxide yellow; iron oxide red - indicated for use as second-line tharapy in patients with chronic lymphocytic leukaemia (cll). indications as at 6 april 2004: for the treatment of b-cell chronic lymphocytic leukaemia.

Velká Británie - angličtina - MHRA (Medicines & Healthcare Products Regulatory Agency)

teva uk ltd - fludarabine phosphate - solution for injection - 25mg/1ml